摘要: 1. Early patient and graft survival are excellent after liver transplantation. 2. The focus must be on reducing toxicity associated with long-term immunosuppression. 3. Available new drugs offer the potential to reduce by combination therapy or replacement of toxic agents. 4. Individual immunosuppressive protocols should developed. 5. Drug interactions common source significant morbidity.